Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial
Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either...
Saved in:
| Published in: | Current controlled trials in cardiovascular medicine Vol. 19; no. 1; pp. 6 - 11 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central Ltd
04-01-2018
BioMed Central BMC |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia.
Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo.
The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia.
ISRCTN, ISRCTN90094835 . Registered on 18 February 2015. |
|---|---|
| AbstractList | Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia. Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 x 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo. The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia. Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia. Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo. The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia. ISRCTN, ISRCTN90094835 . Registered on 18 February 2015. Background Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia. Methods Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 x 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo. Discussion The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia. Trial registration ISRCTN, ISRCTN90094835. Registered on 18 February 2015. Keywords: Older people, Perindopril, Leucine, Sarcopenia, Physical function, Quality of life, Randomised controlled trial Abstract Background Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia. Methods Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo. Discussion The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia. Trial registration ISRCTN, ISRCTN90094835 . Registered on 18 February 2015. BackgroundSarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia.MethodsLeucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo.DiscussionThe results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia.Trial registrationISRCTN, ISRCTN90094835. Registered on 18 February 2015. |
| ArticleNumber | 6 |
| Audience | Academic |
| Author | Sumukadas, Deepa Kemp, Paul R Donnan, Peter T Hume, Cheryl L Avenell, Alison Hapca, Adrian Witham, Miles D Smith, Karen T Band, Margaret M Struthers, Allan D |
| Author_xml | – sequence: 1 givenname: Margaret M surname: Band fullname: Band, Margaret M organization: Tayside Clinical Trials Unit, University of Dundee/NHS Tayside, Dundee, UK – sequence: 2 givenname: Deepa surname: Sumukadas fullname: Sumukadas, Deepa organization: Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK – sequence: 3 givenname: Allan D surname: Struthers fullname: Struthers, Allan D organization: Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK – sequence: 4 givenname: Alison surname: Avenell fullname: Avenell, Alison organization: Health Services Research Unit, University of Aberdeen, Aberdeen, UK – sequence: 5 givenname: Peter T surname: Donnan fullname: Donnan, Peter T organization: Population Health Sciences Division, University of Dundee, Dundee, UK – sequence: 6 givenname: Paul R surname: Kemp fullname: Kemp, Paul R organization: Molecular Medicine, National Heart and Lung Institute, Imperial College, London, UK – sequence: 7 givenname: Karen T surname: Smith fullname: Smith, Karen T organization: Tayside Clinical Trials Unit, University of Dundee/NHS Tayside, Dundee, UK – sequence: 8 givenname: Cheryl L surname: Hume fullname: Hume, Cheryl L organization: Tayside Clinical Trials Unit, University of Dundee/NHS Tayside, Dundee, UK – sequence: 9 givenname: Adrian surname: Hapca fullname: Hapca, Adrian organization: Population Health Sciences Division, University of Dundee, Dundee, UK – sequence: 10 givenname: Miles D surname: Witham fullname: Witham, Miles D email: m.witham@dundee.ac.uk, m.witham@dundee.ac.uk, m.witham@dundee.ac.uk organization: School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK. m.witham@dundee.ac.uk |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29301558$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUl2LEzEUDbLi7lZ_gC8S8EUfZk0mH5P4IJSy6kLBF30OmeROmzKdjMnMwv5703ZdtyAJ5HJzzuGey7lGF0McAKG3lNxQquSnTBmRrCK0qWqmSaVfoCvacFHJmoqLZ_Ulus55RwhnmvFX6LLWjFAh1BWa1zC7MAC2g8fL1S0Owza0YYopY5vxtIVkxwAZdzHhbJOLIwzB4g_rA3hKwfYfP-M8zf4BjylO0cX-iLU4Fcm4Dxk8dnGYUuz7Uh4pr9HLzvYZ3jy-C_Tr6-3P1fdq_ePb3Wq5rpyQZKqoBOkaLzomaeO8cwcDhFinCECtW8dEJ0GVy3Rp2JqCajwvSCo0Z4wt0N1J10e7M2MKe5seTLTBHBsxbYxNU3A9GCUEUZZ3tmWOd53XnDcWWN0SWvbm6qL15aQ1zu0evINiyfZnouc_Q9iaTbw3ohFMSFUE3j8KpPh7hjyZXZzTUPybutGiVlQp-Q-1sWWqMHSxiLmyRmeWoqZcS1a2sEA3_0GV42EfyrahC6V_RqAngksx5wTd0-CUmEOYzClMpoTJHMJkdOG8e-74ifE3PewPB4fGJQ |
| CitedBy_id | crossref_primary_10_1016_j_cld_2020_08_004 crossref_primary_10_1002_jcsm_12934 crossref_primary_10_4103_jmgims_jmgims_80_20 crossref_primary_10_1016_j_exger_2018_06_001 crossref_primary_10_1371_journal_pone_0292402 crossref_primary_10_1007_s40266_018_0566_y crossref_primary_10_3390_biomedicines9050492 crossref_primary_10_2147_CIA_S245595 crossref_primary_10_1007_s00223_019_00561_w crossref_primary_10_1186_s12877_022_03077_5 crossref_primary_10_1016_j_exger_2022_111884 crossref_primary_10_1371_journal_pone_0294330 crossref_primary_10_2174_1874467216666230308142137 crossref_primary_10_1002_agm2_12168 crossref_primary_10_47102_annals_acadmedsg_V48N11p363 crossref_primary_10_1007_s00439_020_02240_5 crossref_primary_10_1016_j_smhs_2020_10_001 crossref_primary_10_3310_LLBX6901 crossref_primary_10_1002_rco2_38 crossref_primary_10_1080_14656566_2019_1622093 crossref_primary_10_1016_j_cvsm_2020_05_001 crossref_primary_10_1080_17474124_2020_1810563 crossref_primary_10_1097_MCO_0000000000000496 crossref_primary_10_3389_fmed_2020_00180 crossref_primary_10_36290_vnl_2018_149 crossref_primary_10_7861_clinmed_2019_0283 crossref_primary_10_1007_s15006_019_0455_2 crossref_primary_10_3390_ijerph18126594 crossref_primary_10_1093_ageing_afab084 crossref_primary_10_1152_japplphysiol_00798_2019 crossref_primary_10_3390_ijerph20105891 crossref_primary_10_1097_BSD_0000000000001283 crossref_primary_10_3233_JAD_230201 |
| Cites_doi | 10.1093/geronj/49.2.M85 10.1093/gerona/glt142 10.1503/cmaj.061339 10.1016/j.biocel.2013.05.035 10.3945/jn.111.138495 10.1111/j.1365-2265.2011.04148.x 10.1093/hmg/ddt514 10.3945/ajcn.2008.26668 10.1056/NEJM199503023320902 10.3317/jraas.2008.011 10.1016/j.jamda.2012.05.020 10.2337/diacare.26.3.625 10.1007/s00223-015-0022-5 10.1016/j.clnu.2012.01.005 10.1016/j.clnu.2014.07.010 10.1089/jir.2010.0043 10.1016/S0140-6736(02)08024-8 10.1126/scitranslmed.3002227 10.1016/S0735-1097(99)00495-7 10.1111/j.1532-5415.2004.52265.x 10.1097/MCO.0b013e328336f6b8 10.1007/s12603-014-0559-4 10.1111/j.1532-5415.2010.02820.x 10.1113/jphysiol.2006.110742 10.1093/ageing/afu115 10.1016/j.peptides.2012.09.016 10.1007/s40266-015-0288-3 10.1002/jcsm.12096 10.1093/gerona/glu010 10.1002/emmm.201100133 10.1016/j.clnu.2012.09.002 10.1002/jcsm.12078 10.1111/j.1532-5415.2006.00701.x 10.1097/CCM.0b013e318274671b 10.1016/j.jamda.2012.07.005 10.1371/journal.pone.0169548 10.1093/ageing/afq034 10.1096/fj.04-2640fje 10.1242/dmm.023390 10.1136/thoraxjnl-2012-203129 10.1183/13993003.01881-2016 10.1152/jappl.2000.89.2.465 10.1007/BF02982709 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 BioMed Central Ltd. The Author(s). 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2018 |
| Copyright_xml | – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: The Author(s). 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2018 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 5PM DOA |
| DOI | 10.1186/s13063-017-2390-9 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database (ProQuest) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
| DatabaseTitleList | MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_85508a4fab3c4ffd9447ae32b01004c2 A521496304 10_1186_s13063_017_2390_9 29301558 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | United Kingdom United Kingdom--UK |
| GeographicLocations_xml | – name: United Kingdom – name: United Kingdom--UK |
| GrantInformation_xml | – fundername: Chief Scientist Office grantid: HSRU1 – fundername: Efficacy and Mechanism Evaluation Programme grantid: 13/53/03 – fundername: Department of Health grantid: EME/13/53/03 – fundername: ; grantid: 13/53/03 |
| GroupedDBID | --- -5E -5G -A0 -BR 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ NPM O5R O5S PGMZT PIMPY PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX CITATION 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO FRP K9. PQEST PQQKQ PQUKI PRINS XSB 5PM |
| ID | FETCH-LOGICAL-c560t-16e6c7d5f3617cdcc043900ac80ee29bc35f6e86e839ee2a21e87d4cdc1594333 |
| IEDL.DBID | RPM |
| ISSN | 1745-6215 |
| IngestDate | Tue Oct 22 15:06:59 EDT 2024 Tue Sep 17 21:25:58 EDT 2024 Sat Nov 09 09:36:23 EST 2024 Tue Nov 19 21:02:41 EST 2024 Tue Nov 12 22:40:58 EST 2024 Thu Sep 12 16:45:59 EDT 2024 Sat Nov 02 12:05:17 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Sarcopenia Older people Randomised controlled trial Leucine Perindopril Physical function Quality of life |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c560t-16e6c7d5f3617cdcc043900ac80ee29bc35f6e86e839ee2a21e87d4cdc1594333 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753568/ |
| PMID | 29301558 |
| PQID | 2795281886 |
| PQPubID | 44365 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_85508a4fab3c4ffd9447ae32b01004c2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5753568 proquest_journals_2795281886 gale_infotracmisc_A521496304 gale_infotracacademiconefile_A521496304 crossref_primary_10_1186_s13063_017_2390_9 pubmed_primary_29301558 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-04 |
| PublicationDateYYYYMMDD | 2018-01-04 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-04 day: 04 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2018 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | G Onder (2390_CR23) 2002; 359 D Sumukadas (2390_CR22) 2007; 177 LA Burton (2390_CR15) 2011; 75 TK Malmstrom (2390_CR27) 2013; 2 I Janssen (2390_CR48) 2000; 89 D Cuthbertson (2390_CR5) 2005; 19 MG Morales (2390_CR37) 2016; 9 SL Casperson (2390_CR6) 2012; 31 D Sumukadas (2390_CR26) 2014; 69 AJ Cruz Jentoft (2390_CR3) 2014; 43 WN Wennie Huang (2390_CR34) 2010; 58 AJ Cruz-Jentoft (2390_CR4) 2010; 39 JM Guralnik (2390_CR33) 1995; 332 SD Berry (2390_CR41) 2013; 2 L Gullestad (2390_CR17) 1999; 34 M Tieland (2390_CR20) 2012; 13 T Yoshida (2390_CR38) 2013; 45 PM Abadir (2390_CR13) 2012; 38 S Verhoeven (2390_CR19) 2009; 89 GJ Dietze (2390_CR16) 2008; 9 MS Patel (2390_CR39) 2016; 7 LJ Loon van (2390_CR10) 2003; 26 M Leenders (2390_CR47) 2011; 141 MJ Acuña (2390_CR36) 2014; 23 SA Studenski (2390_CR30) 2014; 69 2390_CR49 2390_CR45 PM Abadir (2390_CR12) 2011; 31 M Tieland (2390_CR21) 2012; 13 FM Franssen (2390_CR29) 2014; 448 SA Bloch (2390_CR40) 2013; 41 D Sumukadas (2390_CR11) 2008; 12 S Perera (2390_CR46) 2006; 54 B Komar (2390_CR18) 2015; 19 JM Guralnik (2390_CR32) 1994; 49 D Cacchiarelli (2390_CR42) 2011; 3 G Sergi (2390_CR28) 2015; 34 RB Haynes (2390_CR31) 2008; 2 2390_CR35 BT Wall (2390_CR7) 2013; 32 C Beaudart (2390_CR1) 2017; 12 BM Di (2390_CR24) 2004; 52 A Donaldson (2390_CR43) 2013; 68 A Lewis (2390_CR44) 2016; 7 M Balage (2390_CR9) 2010; 13 JE Morley (2390_CR2) 2016; 98 TN Burks (2390_CR14) 2011; 3 I Rieu (2390_CR8) 2006; 575 LS Zhou (2390_CR25) 2015; 32 |
| References_xml | – volume: 49 start-page: M85 issue: 2 year: 1994 ident: 2390_CR32 publication-title: J Gerontol doi: 10.1093/geronj/49.2.M85 contributor: fullname: JM Guralnik – ident: 2390_CR35 – volume: 69 start-page: 736 year: 2014 ident: 2390_CR26 publication-title: J Gerontol A Biol Sci Med Sci. doi: 10.1093/gerona/glt142 contributor: fullname: D Sumukadas – volume: 2 start-page: 129 issue: 3 year: 2013 ident: 2390_CR41 publication-title: J Frailty Aging contributor: fullname: SD Berry – volume: 177 start-page: 867 issue: 8 year: 2007 ident: 2390_CR22 publication-title: CMAJ doi: 10.1503/cmaj.061339 contributor: fullname: D Sumukadas – volume: 45 start-page: 2322 issue: 10 year: 2013 ident: 2390_CR38 publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2013.05.035 contributor: fullname: T Yoshida – volume: 141 start-page: 1070 issue: 6 year: 2011 ident: 2390_CR47 publication-title: J Nutr doi: 10.3945/jn.111.138495 contributor: fullname: M Leenders – volume: 75 start-page: 725 issue: 6 year: 2011 ident: 2390_CR15 publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2011.04148.x contributor: fullname: LA Burton – volume: 23 start-page: 1237 issue: 5 year: 2014 ident: 2390_CR36 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddt514 contributor: fullname: MJ Acuña – volume: 89 start-page: 1468 issue: 5 year: 2009 ident: 2390_CR19 publication-title: Am J Clin Nutr doi: 10.3945/ajcn.2008.26668 contributor: fullname: S Verhoeven – volume: 332 start-page: 556 issue: 9 year: 1995 ident: 2390_CR33 publication-title: N Engl J Med doi: 10.1056/NEJM199503023320902 contributor: fullname: JM Guralnik – volume: 9 start-page: 75 issue: 2 year: 2008 ident: 2390_CR16 publication-title: J Renin Angiotensin Aldosterone Syst doi: 10.3317/jraas.2008.011 contributor: fullname: GJ Dietze – volume: 2 start-page: CD000011 year: 2008 ident: 2390_CR31 publication-title: Cochrane Database Syst Rev. contributor: fullname: RB Haynes – volume: 13 start-page: 713 issue: 8 year: 2012 ident: 2390_CR21 publication-title: J Am Med Dir Assoc doi: 10.1016/j.jamda.2012.05.020 contributor: fullname: M Tieland – volume: 26 start-page: 625 issue: 3 year: 2003 ident: 2390_CR10 publication-title: Diabetes Care doi: 10.2337/diacare.26.3.625 contributor: fullname: LJ Loon van – volume: 98 start-page: 319 issue: 4 year: 2016 ident: 2390_CR2 publication-title: Calcif Tissue Int doi: 10.1007/s00223-015-0022-5 contributor: fullname: JE Morley – volume: 31 start-page: 512 issue: 4 year: 2012 ident: 2390_CR6 publication-title: Clin Nutr doi: 10.1016/j.clnu.2012.01.005 contributor: fullname: SL Casperson – volume: 34 start-page: 667 year: 2015 ident: 2390_CR28 publication-title: Clin Nutr. doi: 10.1016/j.clnu.2014.07.010 contributor: fullname: G Sergi – volume: 448 start-page: e1 year: 2014 ident: 2390_CR29 publication-title: J Am Med Direct Assoc. contributor: fullname: FM Franssen – volume: 31 start-page: 471 issue: 6 year: 2011 ident: 2390_CR12 publication-title: J Interferon Cytokine Res doi: 10.1089/jir.2010.0043 contributor: fullname: PM Abadir – volume: 2 start-page: 55 issue: 1 year: 2013 ident: 2390_CR27 publication-title: J Frailty Aging contributor: fullname: TK Malmstrom – volume: 359 start-page: 926 issue: 9310 year: 2002 ident: 2390_CR23 publication-title: Lancet doi: 10.1016/S0140-6736(02)08024-8 contributor: fullname: G Onder – ident: 2390_CR49 – volume: 3 start-page: 82ra37 issue: 82 year: 2011 ident: 2390_CR14 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002227 contributor: fullname: TN Burks – volume: 34 start-page: 2061 issue: 7 year: 1999 ident: 2390_CR17 publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(99)00495-7 contributor: fullname: L Gullestad – volume: 52 start-page: 961 issue: 6 year: 2004 ident: 2390_CR24 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.2004.52265.x contributor: fullname: BM Di – volume: 13 start-page: 265 issue: 3 year: 2010 ident: 2390_CR9 publication-title: Curr Opin Clin Nutr Metab Care doi: 10.1097/MCO.0b013e328336f6b8 contributor: fullname: M Balage – volume: 19 start-page: 437 issue: 4 year: 2015 ident: 2390_CR18 publication-title: J Nutr Health Aging doi: 10.1007/s12603-014-0559-4 contributor: fullname: B Komar – volume: 58 start-page: 844 issue: 5 year: 2010 ident: 2390_CR34 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.2010.02820.x contributor: fullname: WN Wennie Huang – volume: 575 start-page: 305 issue: Pt 1 year: 2006 ident: 2390_CR8 publication-title: J Physiol doi: 10.1113/jphysiol.2006.110742 contributor: fullname: I Rieu – volume: 43 start-page: 748 year: 2014 ident: 2390_CR3 publication-title: Age Ageing doi: 10.1093/ageing/afu115 contributor: fullname: AJ Cruz Jentoft – volume: 38 start-page: 437 issue: 2 year: 2012 ident: 2390_CR13 publication-title: Peptides doi: 10.1016/j.peptides.2012.09.016 contributor: fullname: PM Abadir – volume: 32 start-page: 727 issue: 9 year: 2015 ident: 2390_CR25 publication-title: Drugs Aging doi: 10.1007/s40266-015-0288-3 contributor: fullname: LS Zhou – volume: 7 start-page: 436 issue: 4 year: 2016 ident: 2390_CR39 publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12096 contributor: fullname: MS Patel – volume: 69 start-page: 547 year: 2014 ident: 2390_CR30 publication-title: J Gerontol A Biol Sci Med Sci. doi: 10.1093/gerona/glu010 contributor: fullname: SA Studenski – volume: 3 start-page: 258 issue: 5 year: 2011 ident: 2390_CR42 publication-title: EMBO Mol Med doi: 10.1002/emmm.201100133 contributor: fullname: D Cacchiarelli – volume: 32 start-page: 412 issue: 3 year: 2013 ident: 2390_CR7 publication-title: Clin Nutr doi: 10.1016/j.clnu.2012.09.002 contributor: fullname: BT Wall – volume: 7 start-page: 330 issue: 3 year: 2016 ident: 2390_CR44 publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12078 contributor: fullname: A Lewis – volume: 54 start-page: 743 issue: 5 year: 2006 ident: 2390_CR46 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.2006.00701.x contributor: fullname: S Perera – volume: 41 start-page: 982 issue: 4 year: 2013 ident: 2390_CR40 publication-title: Crit Care Med doi: 10.1097/CCM.0b013e318274671b contributor: fullname: SA Bloch – volume: 13 start-page: 720 issue: 8 year: 2012 ident: 2390_CR20 publication-title: J Am Med Dir Assoc doi: 10.1016/j.jamda.2012.07.005 contributor: fullname: M Tieland – volume: 12 start-page: e0169548 issue: 1 year: 2017 ident: 2390_CR1 publication-title: PLoS One doi: 10.1371/journal.pone.0169548 contributor: fullname: C Beaudart – volume: 39 start-page: 412 issue: 4 year: 2010 ident: 2390_CR4 publication-title: Age Ageing doi: 10.1093/ageing/afq034 contributor: fullname: AJ Cruz-Jentoft – volume: 19 start-page: 422 issue: 3 year: 2005 ident: 2390_CR5 publication-title: FASEB J doi: 10.1096/fj.04-2640fje contributor: fullname: D Cuthbertson – volume: 9 start-page: 441 issue: 4 year: 2016 ident: 2390_CR37 publication-title: Mas Dis Model Mech doi: 10.1242/dmm.023390 contributor: fullname: MG Morales – volume: 68 start-page: 1140 issue: 12 year: 2013 ident: 2390_CR43 publication-title: Thorax doi: 10.1136/thoraxjnl-2012-203129 contributor: fullname: A Donaldson – ident: 2390_CR45 doi: 10.1183/13993003.01881-2016 – volume: 89 start-page: 465 issue: 2 year: 2000 ident: 2390_CR48 publication-title: J Appl Physiol doi: 10.1152/jappl.2000.89.2.465 contributor: fullname: I Janssen – volume: 12 start-page: 480 issue: 7 year: 2008 ident: 2390_CR11 publication-title: J Nutr Health Aging doi: 10.1007/BF02982709 contributor: fullname: D Sumukadas |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.3879333 |
| Snippet | Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality... Background Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and... BackgroundSarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and... Abstract Background Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence,... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 6 |
| SubjectTerms | Absorptiometry, Photon Activities of Daily Living Aged Angiotensin converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - adverse effects Angiotensin-Converting Enzyme Inhibitors - therapeutic use Dietary Supplements - adverse effects Dosage and administration Drug therapy Elderly Female Fitness training programs Frailty Geriatric Assessment Growth hormones Health aspects Heart failure Humans Inflammation Intervention Leucine Leucine - adverse effects Leucine - therapeutic use Male Mortality Multicenter Studies as Topic Muscle strength Muscle Strength - drug effects Muscle, Skeletal - diagnostic imaging Muscle, Skeletal - drug effects Muscle, Skeletal - physiopathology Musculoskeletal system Older people Perindopril Perindopril - adverse effects Perindopril - therapeutic use Pharmaceutical industry Physical function Polypharmacy Protein synthesis Proteins Quality of Life Randomized Controlled Trials as Topic Sarcopenia Sarcopenia - diagnostic imaging Sarcopenia - drug therapy Sarcopenia - physiopathology Study Protocol Time Factors Treatment Outcome United Kingdom |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3BbtQwEB2VHhAXVKBAoEU-IFGQomZjJ3G4bctWPbRcWiRuljO21Ugoi0j3_ztjZ1eNOHBB2kPkzEremfHMm7X9BuBjYFKysgvkvF7lymHIbaCq1bumkxXqyku-O3x503z_qb-tmCZn1-qLz4QleuCkuFMm3NJWBdtJVCG4VqnGell2BXOdYYq-Rb0tplIMpiwr1bSHudD16UiRmvcrKSKXVOTn7SwLRbL-v0Pyo5w0Py_5KAFdHMDzCTmKZZrxC9jzw0t4ej3tjb-CzZXf8JOwgxPL85Xoh7u-67mbjrCjSBetqC4WBFPFSP7NjbN6K06uWDh27_j8VUS6WcHsDWtykShrBeUztyaH8E5MR9t_0WP8yiH8uFjdnl_mU1OFHAnc3OeL2tfYuCpIwi7oEFlZRWFRF96XbYeyCrXX9JEtDdhy4XXjFEkS8FFSytewP6wH_xaEpBGHhAhKMkonbYtUbCJBAuetxeAy-LJVsvmduDNMrDl0bZJFDFnEsEVMm8EZm2EnyLTXcYCcwUzOYP7lDBl8YiMaXpxkKbTTHQOaL9NcmSWBFUUhp1AZHM0kSYc4f711AzMt6tGUTVsxeZauM3iTPGI3XUJNjD51Bs3MV2a_Z_5m6O8inTcBZlnV-t3_UMB7eEaITsf_iNQR7N__2fhjeDK6zYe4QB4AmtgUtw priority: 102 providerName: Directory of Open Access Journals |
| Title | Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29301558 https://www.proquest.com/docview/2795281886 https://pubmed.ncbi.nlm.nih.gov/PMC5753568 https://doaj.org/article/85508a4fab3c4ffd9447ae32b01004c2 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB26OZReSr_rJg06FPoBzu5asi33tt1uyCEphbbQm5BHUmJIvCHO_v_MyHaI6a2wByPLrKx50ryxRk8AHwKLkmV1IPB6lSqHIbWBolbvylrmqHMvee_wya_yx1_9fcMyOfm4FyYm7WPdHLWXV0dtcxFzK6-vcD7mic1_nq2JYsi80PMZzIgbjiF6P_2Sg5VqWL5c6mLe0STNS5U0GWcU36csE0oujqmCnviiKNn_78T8wDNNsyYfuKHjZ_B04I9i1bfzOTzy7Qt4fDaskL-E3anf8ZWwrROr9UY07UVTN3ymjrCd6LdbUXQsiKyKjlDOx2c1Vnw65crxDI_PX0UUnRWs4bAloMS6VpBXc1uChXdiSHC_pMv4yCv4c7z5vT5Jh6MVUiSKc5suC19g6fIgicGgQ-R-Wyws6oX3WVWjzEPhNf1kRQU2W3pdOkU1if4oKeVr2Gu3rX8LQlKJQ-IFWaVULW2FFHIiEQPnrcXgEvgydrK57hU0TIw8dGF64xgyjmHjmCqBb2yG-4osfh0LtjfnZoCAYQ02bVWwtUQVgqP_La2XWb1g-TvMEvjIRjQ8RMlSaIedBtReFrsyK6IsiiaehUrgYFKT-hCnt0cYmGFodyYrq5wltHSRwJseEffNHYGVQDnByuR9pncI41HUe8D0u_9-ch-eEJnT8fOQOoC925udfw-zzu0O44eGwzhM7gAgBBZB |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RIgGX8iwECviAxENKNxs7icNtWbZaxG6FRJG4WY4fNFKbrZru_--Mk1SNuFXaQ2RPtIlnPPNNPP4M8METKVlaeTReJ2JhjY-1x6zV2aLimZGZ47R3ePm7OP4rvy-IJicb9sKEon1T1YfN2flhU5-G2sqLczMZ6sQmv9ZzhBg8y-VkB-7jfE2SIUnvHDCGWC76BcypzCctumlarER3nGKGHxNRKAY5AgtyFI0Caf__rvlWbBrXTd4KREeP7_gKT2CvR55s1nU_hXuueQYP1v3a-nPYrtyWrphuLJvNF6xuTuuqptN4mG5Zt1EL82qGMJe1OD_o4K1as08rEg6nf3z-ygJdLSP2hw2aWJDVDOOh3aBBOcv60vgzvAy3vIA_R4uT-TLuD2WIDYKjq3iau9wUNvMcsY-xxtB4J4k2MnEuLSvDM587iT9eYoNOp04WVqAkAifBOd-H3WbTuFfAOLZYg4giLYWouC4NJqsGIYV1WhtvI_gyKEdddNwbKuQsMledUhUqVZFSVRnBN1LfjSDRZoeGzeU_1Y-8IvY2qYXXFTfCe4v_W2jH0yoh4jyTRvCRlK9ocqOGje73KODzEk2WmiHYEeiyEhHBwUgSx9CMuwfzUb1TaFValBmRb8k8gpedJd087mCQERQjGxu9z7gHTSvQgfem9PrOd76Hh8uT9Uqtfhz_fAOPEBLK8JFJHMDu1eXWvYWd1m7fhUl2Df1jKts |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB6aFEIvfT_cpq0OhT7AsdeSbbm37WaXlG5CoC30JmQ9GkPiXeLs_--M7F1iemvBByOPsa0ZzXxjjT4BvPNESpbVHo3XiVhY42PtMWt1tqx5bmTuOK0dPvlenv2Sx3Oiydlt9RWK9k3dHLWXV0dtcxFqK9dXJtnWiSXnpzOEGDwvZLK2PtmDuzhm02ybqPdOGMMsF8Mk5kQWSYeumiYs0SVnmOXHRBaKgY4AgxxFpEDc_7d7vhWfxrWTt4LR4sF_fMZDuD8gUDbtRR7BHdc-hoPTYY79CWyWbkNnTLeWTWdz1rQXTd3QrjxMd6xfsIX5NUO4yzocJ7QBV6PZhyUJh11APn5mgbaWEQvECk0tyGqGcdGu0LCcZUOJ_CWehluews_F_MfsJB42Z4gNgqSbeFK4wpQ29xwxkLHGUJ-nqTYydS6rasNzXziJB6-wQWcTJ0srUBIBlOCcP4P9dtW6F8A4tliDyCKrhKi5rgwmrQahhXVaG28j-LRVkFr3HBwq5C6yUL1iFSpWkWJVFcEXUuFOkOizQ8Pq-rcael8Ri5vUwuuaG-G9xeeW2vGsTolAz2QRvCcDUDTIUctGD2sV8H2JLktNEfQIdF2piOBwJIl9aMaXtyakBufQqaysciLhkkUEz3tr2r3u1igjKEd2Nvqe8RU0r0ALPpjTy3--8y0cnB8v1PLr2bdXcA-RoQz_msQh7N9cb9xr2Ovs5k0YZ38AX1ctWw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Leucine+and+ACE+inhibitors+as+therapies+for+sarcopenia+%28LACE+trial%29%3A+study+protocol+for+a+randomised+controlled+trial&rft.jtitle=Current+controlled+trials+in+cardiovascular+medicine&rft.au=Band%2C+Margaret+M&rft.au=Sumukadas%2C+Deepa&rft.au=Struthers%2C+Allan+D&rft.au=Avenell%2C+Alison&rft.date=2018-01-04&rft.pub=BioMed+Central&rft.eissn=1745-6215&rft.volume=19&rft.issue=1&rft.spage=6&rft_id=info:doi/10.1186%2Fs13063-017-2390-9&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |